Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Notes Payables: 2015-2022

Historic Notes Payables for Seres Therapeutics (MCRB) over the last 1 years, with Dec 2022 value amounting to $456,000.

  • Seres Therapeutics' Notes Payables was N/A to $456,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $456,000, marking a year-over-year change of. This contributed to the annual value of $456,000 for FY2022, which is N/A change from last year.
  • Per Seres Therapeutics' latest filing, its Notes Payables stood at $456,000 for Q4 2022, which was down 95.12% from $9.3 million recorded in Q3 2021.
  • Seres Therapeutics' Notes Payables' 5-year high stood at $9.3 million during Q3 2021, with a 5-year trough of $454,000 in Q4 2020.
  • In the last 3 years, Seres Therapeutics' Notes Payables had a median value of $3.3 million in 2021 and averaged $4.0 million.